CD8A and neoplasm: Despite a low frequency of CD8+ RepTILs (Figure 3A), the tumor implant of patient 8 had a more dramatic fold increase in CD103+CD8+ TRM cells after trametinib treatment than untreated PDX mice (Figure 4C).